Product Description
Ampicillin is used to treat certain infections that are caused by bacteria such as meningitis (infection of the membranes that surround the brain and spinal cord); and infections of the throat, sinuses, lungs, reproductive organs, urinary tract, and gastrointestinal tract. Ampicillin is in a class of medications called penicillins. It works by killing bacteria. (Sourced from: https://medlineplus.gov/druginfo/meds/a685002.html)
Mechanisms of Action: PBP Antagonist, Cell Wall Synthesis Inhibitor
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Intravenous
FDA Designation: *
Approval Status: Approved
Approved Countries: Argentina | Australia | Austria | Bangladesh | Bosnia | Brazil | Bulgaria | Canada | Chile | China | Colombia | Croatia | Cyprus | Czech | Denmark | Dominican Republic | Ecuador | Egypt | Estonia | Finland | France | Germany | Greece | Hong Kong | Hungary | Iceland | India | Indonesia | Ireland | Israel | Italy | Japan | Jordan | Korea | Latvia | Lebanon | Lithuania | Malaysia | Malta | Mexico | Morocco | New Zealand | Norway | Pakistan | Peru | Philippines | Poland | Portugal | Romania | Russia | Saudi Arabia | Serbia | Singapore | Slovakia | Slovenia | South Africa | Spain | Sri Lanka | Sweden | Taiwan | Thailand | Tunisia | Turkey | Ukraine | United Arab Emirates | United Kingdom | United States | Uruguay | Venezuela | Vietnam
Approved Indications: None
Known Adverse Events: None
Company: Pfizer
Company Location: Eastern America
Company CEO: Albert Bourla
Additional Commercial Interests: None
Clinical Description
Countries in Clinic: Kenya, Spain
Active Clinical Trial Count: 3
Recent & Upcoming Milestones
Highest Development Phases
Phase 3: Fractures, Open|Pneumonia
Trial ID |
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|---|
2023-508442-18-00 |
DURATIOM | P3 |
Not yet recruiting |
Fractures, Open |
2027-12-31 |
2025-05-02 |
Treatments |
|
NCT04041791 |
SEARCH | P3 |
Completed |
Pneumonia |
2024-04-05 |
2024-05-23 |
Primary Completion Date|Primary Endpoints|Study Completion Date |
|
2020-001397-30 |
2020-001397-30 | P3 |
Active, not recruiting |
Unknown |
2024-09-03 |
2022-03-13 |
Treatments |
Recent News Events
Date |
Type |
Title |
|---|---|---|
|
01/08/2026 |
News Article |
Avenacy Provides Update on Business Progress and Announces 2026 Strategic Priorities Ahead of 44th Annual J.P. Morgan Healthcare Conference |
|
06/09/2025 |
News Article |
Discovery Suggests Method to Offset Antibiotic-Caused Harm to Infant Immune Systems |
|
04/16/2025 |
News Article |
Basilea reports presentation of new data for fosmanogepix, isavuconazole (Cresemba®) and ceftobiprole (Zevtera®) at ESCMID Global 2025 |
|
03/17/2025 |
News Article |
Avenacy Announces Launch of Five Injectable Antibiotic Products in the U.S. Market |